During the past decade, Henry Ford Health System conducted 431 clinical trials. In the 10-year time frame, 431 clinical trials started and 219 clinical trials were completed, i.e. on average, 50.8% percent of trials that started reached the finish line to date. In the past 5 years, 196 clinical trials started and 123 clinical trials were completed. i.e. 62.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Henry Ford Health System" #1 sponsor was "Henry Ford Health System" with 60 trials, followed by "Gilead Sciences" with 45 trials sponsored, "Hoffmann-La Roche" with 16 trials sponsored, "Bristol-Myers Squibb" with 15 trials sponsored and "National Institute of Allergy and Infectious Diseases (NIAID)" with 15 trials sponsored. Other sponsors include 554 different institutions and companies that sponsored additional 334 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Henry Ford Health System" #1 collaborator was "Henry Ford Health System" with 16 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 16 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 14 trials as a collaborator, "Merck Sharp & Dohme LLC" with 12 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 11 trials as a collaborator. Other collaborators include 411 different institutions and companies that were collaborators in the rest 283 trials.

According to Clinical.Site data, the most researched conditions in "Henry Ford Health System" are "Asthma" (19 trials), "Breast Cancer" (19 trials), "Heart Failure" (18 trials), "Glioblastoma Multiforme" (11 trials) and "Prostate Cancer" (11 trials). Many other conditions were trialed in "Henry Ford Health System" in a lesser frequency.

Most popular intervention types in "Henry Ford Health System" are "Drug" (457 trials), "Device" (97 trials), "Biological" (67 trials), "Other" (59 trials) and "Procedure" (34 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (106 trials), "Pembrolizumab" (12 trials), "Carboplatin" (11 trials), "Bevacizumab" (9 trials) and "Cisplatin" (9 trials). Other intervention names were less common.

The vast majority of trials in "Henry Ford Health System" are 662 trials for "All" genders, 31 trials for "Female" genders and 17 trials for "Male" genders.

Currently, there are NaN active trials in "Henry Ford Health System". undefined are not yet recruiting, 119 are recruiting, 79 are Active, not recruiting, and 6 are Enrolling by invitation. In total, there were 393 completed trials in Henry Ford Health System, undefined suspended trials, and 74 terminated clinical trials to date.

Out of the total trials that were conducted in Henry Ford Health System, 79 "Phase 1" clinical trials were conducted, 200 "Phase 2" clinical trials and 226 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 28 trials, and there were also 100 trials that are defined as “Not Applicable".